Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Wali
Ravinder K
RK
University of Maryland School of Medicine, Baltimore, MD, USA. ravinder.wali@inova.org
Iyengar
Malini
M
Beck
Gerald J
GJ
Chartyan
David M
DM
Chonchol
Michel
M
Lukas
Mary Ann
MA
Cooper
Christopher
C
Himmelfarb
Jonathan
J
Weir
Matthew R
MR
Berl
Tomas
T
Henrich
William L
WL
Cheung
Alfred K
AK
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077261:Carvedilol; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005919:Glomerular Filtration Rate / Q000502:physiology; D054143:Heart Failure, Systolic / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D003404:Creatinine